Tumors escape CD4+ T-cell-mediated immunosurveillance by impairing the ability of infiltrating macrophages to indirectly present tumor antigens

Cancer Research

Volumn 75, Issue 16, 2015, Pages 3268-3278

  Tveita, Anders Aune ^a   Schjesvold, Fredrik ^a   Haabeth, Ole Audun ^a   Fauskanger, Marte ^a   Bogen, Bjarne ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; IMMUNOSURVEILLANCE; MACROPHAGE FUNCTION; MOLECULAR RECOGNITION; MOUSE; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN QUATERNARY STRUCTURE; SCID MOUSE; TH1 CELL; TRANSGENIC MOUSE; TUMOR ESCAPE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CBA MOUSE; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; IMMUNOLOGY; MACROPHAGE; METABOLISM; MULTIPLE MYELOMA; PATHOLOGY; SURVIVAL; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOLOGIC SURVEILLANCE; MACROPHAGES; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, SCID; MICE, TRANSGENIC; MULTIPLE MYELOMA; SURVIVAL ANALYSIS; TUMOR ESCAPE;

EID: 84942896216     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3640     Document Type: Article

References (43)

1. Schreiber H, WuTH, Nachman J, KastWM. Immunodominance and tumor escape. Semin Cancer Biol 2002;12:25-31.
2. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
3. Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 2012;72:3125-30.
4. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.
5. Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005;174:2591-601.
6. Gao FG, Khammanivong V, Liu WJ, Leggatt GR, Frazer IH, Fernando GJP. Antigen-specific CD4(+) T-cell help is required to activate a memory CD8(+) T cell to a fully functional tumor killer cell. Cancer Res 2002;62:6438-41.
7. Lauritzsen GF, Weiss S, Dembic Z, Bogen B. Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci U S A 1994;91:5700-4.
8. Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, et al. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010;207:651-67.
9. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010;207:637-50.
10. Qin ZH, Blankenstein T. CD4(+) T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000; 12:677-86.
11. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014;344:641-5.
12. Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014;512:324-7.
13. Lundin KU, Screpanti V, Omholt H, Hofgaard PO, Yagita H, Grandien A, et al. CD4+ T cells kill Id+ B-lymphoma cells: FasLigand-Fas interaction is dominant in vitro but is redundant in vivo. Cancer Immunol Immunother 2004;53:1135-45.
14. Perez-Diez A, Joncker NT, Choi K, Chan WFN, Anderson CC, Lantz O, et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007;109:5346-54.
15. Bogen B, Munthe L, Sollien A, Hofgaard P, Omholt H, Dagnaes F, et al. Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies. Eur J Immunol 1995;25:3079-86.
16. Corthay A, Skovseth DK, Lundin KU, Røsjø E, Omholt H, Hofgaard PO, et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005;22:371-83.
17. Dembic Z, Schenck K, Bogen B. Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells. Proc Natl Acad Sci U S A 2000;97:2697-702.
18. Corthay A, Lundin KU, Lorvik KB, Hofgaard PO, Bogen B. Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells. Cancer Res 2009;69:5901-7.
19. Haabeth OA, Lorvik KB, Hammarstrom C, Donaldson IM, Haraldsen G, Bogen B, et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun 2011;2:240.
20. Bogen B, Malissen B, Haas W. Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur J Immunol 1986;16:1373-8.
21. Bogen B, Gleditsch L, Weiss S, Dembic Z. Weak positive selection of transgenic T cell receptor-bearing thymocytes: importance of major histocompatibility complex class II, T cell receptor and CD4 surface molecule densities. Eur J Immunol 1992;22:703-9.
22. Tveita AA, Schjesvold FH, Sundnes O, Haabeth OA, Haraldsen G, Bogen B. Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells. Eur J Immunol 2014;44:2625-37.
23. Norderhaug L, Olafsen T, Michaelsen TE, Sandlie I. Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells. J Immunol Methods 1997;204:77-87.
24. Weiss S, Bogen B. MHC class II-restricted presentation of intracellular antigen. Cell 1991;64:767-76.
25. Lauritzsen GF, Bogen B. The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells. Cell Immunol 1993;148: 177-88.
26. Bogen B, Jørgensen T, Hannestad K. T helper cell recognition of idiotopes on l2 light chains ofM315 and T952: evidence for dependence on somatic mutations in the third hypervariable region. Eur J Immunol 1985;15: 278-81.
27. Kristoffersen G, Hannestad K, Hansen T. Two M315 idiotopes defined by isologous monoclonal antibodies: one depends on germline and the other on mutated murine lambda 2 light chain sequences. Scand J Immunol 1987;26:535-46.
28. Trieu EP, Targoff IN. SDS-PAGE for (3)(5)S immunoprecipitation and immunoprecipitation western blotting. Methods Mol Biol 2012;869: 215-33.
29. Tutturen AE, Fleckenstein B, de Souza GA. Assessing the citrullinome in rheumatoid arthritis synovial fluid with and without enrichment of citrullinated peptides. J Proteome Res 2014;13:2867-73.
30. Dul JL, Aviel S, Melnick J, Argon Y. Ig light chains are secreted predominantly as monomers. J Immunol 1996;157:2969-75.
31. Mosmann TR, Williamson AR. Structural mutations in a mouse immunoglobulin light chain resulting in failure to be secreted. Cell 1980;20: 283-92.
32. Wu GE, Hozumi N, Murialdo H. Secretion of a lambda 2 immunoglobulin chain is prevented by a single amino acid substitution in its variable region. Cell 1983;33:77-83.
33. Grey HM, Colon SM, Chesnut RW. Requirements for the processing of antigen by antigen-presenting B cells. II. Biochemical comparison of the fate of antigen in B cell tumors and macrophages. J Immunol 1982;129: 2389-95.
34. Naquet P, Ellis J, Singh B, Hodges RS, Delovitch TL. Processing and presentation of insulin. I. Analysis of immunogenic peptides and processing requirements for insulin A loop-specific T cells. J Immunol 1987;139: 3955-63.
35. AtassiMZ, Yoshioka M, Bixler GS Jr. T cells specific for alpha-beta interface regions of hemoglobin recognize the isolated subunit but not the tetramer and indicate presentation without processing. Proc Natl Acad Sci U S A 1989;86:6729-33.
36. Atassi MZ, Bixler GS Jr, Yokoi T. Conformation-dependent recognition of a protein by T cells requires presentation without processing. Biochem J 1989;259:731-5.
37. Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, et al. How do CD4 T cells detect and eliminate tumor cells that either lack or express MHC class II molecules? Front Immunol 2014;5:174.
38. Kohler G. Immunoglobulin chain loss in hybridoma lines. Proc Natl Acad Sci U S A 1980;77:2197-9.
39. Wilde CD, Milstein C. Analysis of immunoglobulin chain secretion using hybrid myelomas. Eur J Immunol 1980;10:462-7.
40. White-Gilbertson S, Hua Y, Liu B. The role of endoplasmic reticulum stress in maintaining and targeting multiple myeloma: a double-edged sword of adaptation and apoptosis. Front Genet 2013; 4:109.
41. Magrangeas F, Cormier ML, Descamps G, Gouy N, Lode L, Mellerin MP, et al. Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level. Blood 2004;103:3869-75.
42. Brioli A, Giles H, Pawlyn C, Campbell JP, KaiserMF, Melchor L, et al. Serum free light chain evaluation as a marker for the impact of intra-clonal heterogeneity on the progression and treatment resistance in multiple myeloma. Blood 2014;123:3414-9.
43. Kuhnemund A, Liebisch P, Bauchmuller K, zur Hausen A, Veelken H, Wasch R, et al. 'Light-chain escape-multiple myeloma'-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol 2009;135:477-84.